On Wednesday, the FDA issued a Complete Response Letter (CRL) related to Novo Nordisk A/S’s (NYSE:NVO) Biologics License Application for once-weekly basal insulin icodec for diabetes mellitus. In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the application review can be completed. Related: Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review. Novo Nordisk is evaluating the content of the CRL and ...